Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 2,284 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,284 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $29.78, for a total transaction of $68,017.52. Following the transaction, the general counsel owned 21,904 shares in the company, valued at approximately $652,301.12. This trade represents a 9.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jonathan Allan also recently made the following trade(s):

• On Wednesday, December 3rd, Jonathan Allan sold 2,292 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total transaction of $70,249.80.
• On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $250,700.00.

Stoke Therapeutics Trading Up 3.9%

Shares of Stoke Therapeutics stock traded up $1.15 during midday trading on Wednesday, reaching $30.96. The company had a trading volume of 665,349 shares, compared to its average volume of 1,025,254. The stock has a fifty day simple moving average of $28.58 and a 200 day simple moving average of $19.53. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $38.69. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 46.21 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The firm had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. Sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently added to or reduced their stakes in STOK. XTX Topco Ltd bought a new stake in shares of Stoke Therapeutics during the 1st quarter valued at $267,000. US Bancorp DE boosted its position in shares of Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after acquiring an additional 11,108 shares in the last quarter. Vanguard Group Inc. increased its stake in Stoke Therapeutics by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock valued at $18,515,000 after acquiring an additional 53,004 shares during the last quarter. Invesco Ltd. lifted its stake in Stoke Therapeutics by 117.0% during the first quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock worth $174,000 after purchasing an additional 14,118 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Stoke Therapeutics in the 1st quarter valued at $719,000.

Analysts Set New Price Targets

A number of brokerages recently weighed in on STOK. BTIG Research reaffirmed a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Stoke Therapeutics in a research note on Monday. Chardan Capital raised Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Wedbush upped their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Finally, Canaccord Genuity Group lifted their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $31.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.